We performed a therapeutic study of a PD-1 blocking antibody in two fully immunocompetent genetically engineered mouse models of lung cancer, EGFRT790M/L858R (TL) and KrasG12D using the same dosing schedule as described previously17 (Fig. 1a). Here, PDCD1 is linked to lung carcinoma.